# OnCo record nct06731478 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06731478/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06731478", "NCT06731478" ;
  schema:name "Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer"@en ;
  schema:alternateName "Destiny-Gastric05"@en ;
  schema:description "A phase 3 trial of Trastuzumab deruxtecan, Pembrolizumab and Trastuzumab in gastric & gastro-oesophageal junction cancer, run by Daiichi Sankyo, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06731478/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06731478> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2025-02-27" ;
  onco:cancers <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/gastric-her2-positive/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/trastuzumab/> ;
  onco:companies <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/merck/> .